Alzheimer's disease is a chronic, progressive, neurodegenerative disorder of the brain characterized by deficits in memory and cognitive function. Donepezil is a reversible, noncompetitive cholinesterase inhibitor. It has a high binding specificity for brain acetylcholinesterase, with little to no affinity for butyrylcholinesterase. It is approved by the FDA for the treatment of severe Alzheimer's disease. The aim of this work is to formulate depot injection lipospheres and in situ implants containing Donepezil for ...
Read More
Alzheimer's disease is a chronic, progressive, neurodegenerative disorder of the brain characterized by deficits in memory and cognitive function. Donepezil is a reversible, noncompetitive cholinesterase inhibitor. It has a high binding specificity for brain acetylcholinesterase, with little to no affinity for butyrylcholinesterase. It is approved by the FDA for the treatment of severe Alzheimer's disease. The aim of this work is to formulate depot injection lipospheres and in situ implants containing Donepezil for treatment of Alzheimer disease in order to decrease dosing frequency and increase patient compliance. The work is divided into: Chapter 1: Formulation and In Vitro Evaluation of Injectable Donepezil Lipospheres. Chapter 2: Formulation and In Vitro Evaluation of Injectable Donepezil in Situ Implant. Chapter 3: Comparative Pharmacokinetic Study of Different Injectable Donepezil Formulae.
Read Less
Add this copy of Controlled Release Injection of a Central Nervous to cart. $76.90, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2014 by LAP Lambert Academic Publishing.
Add this copy of Controlled Release Injection of a Central Nervous to cart. $105.66, new condition, Sold by Paperbackshop rated 5.0 out of 5 stars, ships from Bensenville, IL, UNITED STATES, published 2014 by LAP Lambert Academic Publishing.